Your search for apixaban returned 4 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Post remove
Drugs in the Pipeline remove

Your search for apixaban returned 4 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Eliquis Achieves Primary Outcome in Phase 3 VTE Study

Bristol-Myers Squibb and Pfizer announced the results of the Phase 3 AMPLIFY-EXT trial, which evaluated treatment with Eliquis (apixaban) over a one-year period compared to placebo for the prevention of recurrent venous thromboembolism (VTE) in patients who had already completed 6-12 months of anticoagulation treatment for VTE, including deep vein thrombosis (DVT) or pulmonary embolism (PE).
Drugs in the Pipeline

FDA Wants More Data for Anticoagulant Antidote AndexXa

The FDA has issued a Complete Response Letter (CRL) to the Biologics License Application (BLA) of AndexXa (andexanet alfa; Portola) as a reversal agent for life-threatening or uncontrolled bleeding due to Factor Xa inhibitors.
Drugs in the Pipeline

Phase 3 Study of Eliquis for Stroke Prevention

Bristol-Myers Squib and Pfizer announced results from their Phase 3 ARISTOTLE study of Eliquis (apixaban tablet) in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke.